FDA Orange Book · active-ingredient family
Finasteride; tadalafil
Finasteride; tadalafil is approved as 1 brand and 2 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.
Reference-listed drug:ENTADFI · NDA 215423
1
Brand (NDA)
2
Generics (ANDA)
0
Listed patents
0
Exclusivity periods
Brand (NDA) products · capsule
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| ENTADFIRLD | BLUE WATER BIOTECH | NDA 215423 | — | Dec 09, 2021 |
Generic (ANDA) products (2)
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| FINASTERIDE AND TADALAFIL | NOVITIUM PHARMA | ANDA 218499 | — | Mar 19, 2025 | |
| FINASTERIDE AND TADALAFIL | ZYDUS LIFESCIENCES | ANDA 218232 | — | Mar 15, 2024 |
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Finasteride; tadalafil — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

